MiR-363-3p suppresses tumor growth and metastasis of colorectal cancer via targeting SphK2

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Jinlang DongWeiwei Tan

Abstract

Aberrant expression of miR-363-3p is seen in a wide array of cancers. The exact function of miR-363-3p in colorectal cancer (CRC), and the underlying mechanisms remain undefined. In the current study, we observed a down-regulation of miR-363-3p in CRC tissues, along with a strong correlation between low miR-363-3p levels and clinico-pathological parameters like tumor stage and lymph node metastasis. Ectopic overexpression of miR-363-3p in HT29 and HCT116 cell lines effectively inhibited cell proliferation and metastasis, and promoted apoptosis. Concurrently, miR-363-3p inhibition facilitated cell proliferation and suppressed apoptosis. Consistent with the in vitro findings, tumor growth and metastasis were also suppressed by the overexpression of miR-363-3p in vivo. Furthermore, miR-363-3p overexpression resulted in a significant decrease in SphK2 mRNA and protein levels, while miR-363-3p inhibition elevated SphK2 levels in CRC cell lines. Overexpression of SphK2 significantly abrogated the effects of miR-363-3p on cell growth, apoptosis, and metastasis. Taken together, our findings establish miR-363-3p as a potential tumor suppressor in CRC with SphK2 as its downstream target.

References

Jul 10, 2002·Progress in Nucleic Acid Research and Molecular Biology·Hong LiuSarah Spiegel
Sep 5, 2003·The Journal of Biological Chemistry·Nobuaki IgarashiShun-ichi Nakamura
Dec 31, 2003·Cell·Benjamin P LewisChristopher B Burge
Oct 27, 2004·PLoS Biology·Bino JohnDebora S Marks
Jun 14, 2005·The Journal of Biological Chemistry·Nitai C HaitSarah Spiegel
Jan 25, 2008·Nature Reviews. Molecular Cell Biology·Yusuf A Hannun, Lina M Obeid
Feb 26, 2009·Cell·Andrea Ventura, Tyler Jacks
Jul 21, 2009·International Journal of Cancer. Journal International Du Cancer·Andreas WeigertBernhard Brüne
Mar 23, 2010·Current Molecular Pharmacology·Olivier CuvillierPascal Rischmann
May 18, 2010·Investigational New Drugs·Vladimir BeljanskiCharles D Smith
Sep 8, 2011·Molecular Cancer Research : MCR·Peng Gao, Charles D Smith
Oct 18, 2011·Trends in Cell Biology·Michael MaceykaSarah Spiegel
May 22, 2013·Cytogenetic and Genome Research·N MosakhaniS Knuutila
Jan 24, 2014·Nature Communications·Shinnosuke TsujiTetsu Akiyama
Dec 3, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jia-Hui ChuXian-Jun Qu
Sep 5, 2015·Journal of Experimental & Clinical Cancer Research : CR·Cai XunWang Li-Wei
Jan 7, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lan ZhangYanmei Ma
Feb 10, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hongbo TangTao Chen
Mar 12, 2016·Journal of Experimental & Clinical Cancer Research : CR·Yudan Chi, Dongming Zhou
Jun 3, 2016·CA: a Cancer Journal for Clinicians·Kimberly D MillerAhmedin Jemal

❮ Previous
Next ❯

Citations

Jan 10, 2021·Life Sciences·Sepideh MirzaeiMichael R Hamblin
Jul 3, 2021·Cancers·Paulína Pidíková, Iveta Herichová
Oct 13, 2021·Journal of Cellular and Molecular Medicine·Bo FanJiankai Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.